Ketamine Therapy Regulations Spring 2026: Perry Sentencing, Texas Rules, France Authorization, and Federal Policy Shifts
📋 SYNOPSIS
Four major regulatory developments in Spring 2026 signal a coordinated shift toward accountability, structure, and formal oversight in ketamine and psychedelic therapy. The Matthew Perry case resulted in federal prison sentences for physicians who enabled unmonitored ketamine use. France became the first country to authorize IV racemic ketamine for suicidal crisis with strict hospital-based protocols. Texas is finalizing mandatory ketamine clinic regulations expected to pass in June 2026. President Trump signed an executive order fast-tracking psychedelic therapy research and access at the federal level.
Bottom line: The era of unregulated ketamine therapy is ending. Providers without robust documentation systems, monitoring protocols, and structured oversight are running out of runway whether from state medical boards, federal agencies, or legal liability.
💡 KEY TAKEAWAYS
Spring 2026 regulatory developments reveal a clear pattern across legal, international, state, and federal levels:
- Legal accountability is real: Physicians received federal prison sentences in the Perry case for enabling ketamine access outside proper supervision, courts will prosecute providers when oversight fails.
- International frameworks raise the bar: France validated IV racemic ketamine but with strict hospital-based, crisis-only protocols. Creating a potential regulatory template that's narrower than current U.S. practice.
- State boards are defining minimum standards: Texas's pending PKT regulations (vote expected June 2026) establish baseline requirements for clinic registration, physician oversight, and monitoring that other states are watching closely.
- Federal prioritization means federal expectations: Trump's executive order elevates psychedelic therapy to official policy agenda, shifting regulation and monitoring from clinic-level choices to federal-level standards.
Bottom line: Regulatory advantage is shifting toward structure, not flexibility. The providers who position now—with documentation systems, monitoring protocols, and accountable frameworks—will lead the next phase of this field.
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects current regulatory developments and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical or legal advice for specific patients or clinical situations.
Table of Contents
Four Major Developments Reshaping Ketamine and Psychedelic Therapy
Matthew Perry Case: The Final Sentence
France Authorizes IV Ketamine for Suicidal Crisis
Texas Medical Board Update: PKT Rules Still Pending
Trump Executive Order: Federal Fast-Track for Psychedelic Therapy
The REMS Advantage: What Regulatory-Ready Looks Like
Spring 2026 brought four major regulatory developments in ketamine and psychedelic therapy: the Matthew Perry case sentencing, France's IV ketamine authorization, Texas Medical Board PKT rule revisions, and President Trump's federal psychedelic executive order—all signaling a coordinated shift toward formal oversight and accountability.
Four Major Developments Reshaping Ketamine and Psychedelic Therapy
The ketamine and psychedelic therapy landscape recently shifted in four significant ways. And if you're a provider in this space, these aren't isolated news items.
They're connected pieces of a larger pattern that's already reshaping how this field operates.
In the past few weeks:
The Matthew Perry case reached its final sentencing, with the harshest penalties yet for both black-market suppliers and physicians
France became the first country to formally authorize IV racemic ketamine for suicidal crisis with a rigorous regulatory framework attached
Texas moved closer to finalizing comprehensive ketamine clinic regulations that could set the template nationwide
US President Trump signed an executive order fast-tracking psychedelic therapy research and access at the federal level
These developments span courtrooms, international regulatory bodies, state medical boards, and federal agencies.
But they're all pointing in the same direction: accountability, structure, and formal oversight.
For providers who've been operating in the relatively unregulated ketamine space, this is the moment to pay attention.
Not because any single story requires immediate action, but because together, they signal where this field is likely heading.
Matthew Perry Case: The Final Sentence
In April 2026, Jasveen Sangha, who became known in press coverage as the "Ketamine Queen," was sentenced to 15 years in federal prison after pleading guilty to five federal drug charges connected to Matthew Perry's death. She was the central figure in the black-market supply chain that prosecutors say ultimately fed Perry's escalating, at-home ketamine use.
What Happened
To understand how we got here, a quick recap.
Perry was found unresponsive in his Los Angeles home in October 2023. The medical examiner ruled his death an accident, with the primary cause listed as the acute effects of ketamine, with drowning, coronary artery disease, and buprenorphine as contributing factors.
What the investigation revealed was that Perry had been receiving ketamine under legitimate medical supervision for depression, but as his cravings intensified, he began sourcing much higher doses through an entirely separate, unmonitored, illicit network.
The Legal Outcome
By the time the legal dust settled, five people had been charged: two physicians, his personal assistant, and at least one other Hollywood-connected figure.
Dr. Salvador Plasencia, a Santa Monica physician who admitted to distributing ketamine to Perry, was sentenced to 30 months in federal prison. Dr. Mark Chavez, who pleaded guilty to conspiring to distribute ketamine, received eight months of home confinement, three years of supervised release, and 300 hours of community service. And now Sangha, at 15 years, has received the stiffest sentence of the group.
Why This Matters
What stands out about this case, looking at it from within the ketamine therapy community, is how clearly it illustrates a risk that doesn't get talked about enough.
This wasn't a story about a rogue clinic or outright negligence from the start. It began with legitimate, physician-supervised treatment. The breakdown happened at the edges and gray zones. It occurred in the spaces where the clinical relationship loosened, where oversight thinned out, and where a patient who wanted more found a way to fill the need outside of any medical framework.
It was in that gap where this went wrong. And the courts, by handing out sentences that include practicing physicians, are sending a message that the field cannot afford to ignore: when ketamine moves from a supervised clinical setting into unmonitored use, the legal and ethical accountability doesn't disappear. If anything, the trail leads back.
💡 KEY TAKEAWAYS
- Physicians are being held criminally accountable: Dr. Plasencia received 30 months in federal prison for distributing ketamine outside proper medical oversight. This isn't just medical board action, it's federal prosecution.
- The bridge between legitimate and illicit use matters: Perry's case began with supervised medical treatment for depression but escalated when he sought higher doses through black-market channels. The courts traced accountability back through that entire supply chain.
- Sentences reflect the stakes: The "Ketamine Queen" received 15 years, but physicians involved received significant prison time and home confinement. The legal system is treating ketamine-related deaths as drug distribution cases, not accidents.
- Five defendants, one message: Two physicians, a personal assistant, and black-market suppliers were all prosecuted, demonstrating that everyone in the supply chain (from prescriber to dealer) faces legal exposure when ketamine moves outside clinical control.
What This Means for Providers:
When ketamine transitions from supervised clinical settings to unmonitored, at-home use, legal accountability follows the prescribing physician. This case establishes clear precedent: courts will prosecute physicians who enable access to ketamine outside appropriate medical frameworks, even if treatment began legitimately. The gap between clinical oversight and patient access is where legal exposure lives.
France became the first country to formally authorize IV racemic ketamine for severe suicidal crisis in March 2026, establishing a hospital-based framework with strict patient selection, continuous monitoring, and mandatory follow-up protocols that could influence U.S. regulatory standards.
France Authorizes IV Ketamine for Suicidal Crisis: What It Means for U.S. Providers
France has just taken a step that should send a quiet but clear signal to every ketamine clinic and infusion center in the U.S.: in March 2026, French regulators became the first in the world to formally authorize IV racemic ketamine for adults in severe suicidal crisis.
This is a national, hospital-based authorization, tightly framed around acute psychiatric risk and psychiatric supervision.
What France Authorized
For ketamine therapy providers, the critical moment and perhaps significant signal. Racemic IV formulation, now being officially recognized as a rapid-acting tool for one of psychiatry's most urgent problems: imminent suicide risk.
The dosing protocol in the French trials that underpin this decision is familiar: around 0.5 mg/kg over 40 minutes, sometimes followed by a second infusion at 24 hours. But the real story isn't the dosing or the scientific studies. It's the framework being built around it.
The Framework
France's approach is explicitly structured: careful patient selection, continuous monitoring during and after the infusion, and repeated assessment of suicidal ideation immediately afterward and over the following days.
In other words, this isn't "ketamine as a wellness service" or for “at-home use.” It's ketamine as a highly monitored psychiatric intervention, with formal follow-up built into the protocol. For a U.S. industry that's been wrestling with questions about standardization, safety, and regulation, that's not just a clinical model - it's a potential template.
Why This Matters
For the ketamine therapy community, France's decision is both validating and cautionary.
On one side, France's move lends medical legitimacy to IV racemic ketamine in a crisis context, which could eventually ripple into U.S. regulatory thinking and payer attitudes. This is the formulation many in this medical community have been using off-label for years, now receiving formal national authorization in France. That's significant.
But there's another side to consider. France's framework is narrow**,** limited to severe suicidal crisis in hospital-based settings with high-surveillance protocols. The U.S. ketamine therapy community has been treating a much broader scope: treatment-resistant depression, PTSD, chronic pain, and other conditions, often in office-based practices with more flexible approaches.
The question is: could France's strict, crisis-only framework become the regulatory template that others point to? Could regulators looking to formalize ketamine therapy standards say "France proved this works for suicidal crisis with these specific protocols, so now let's require that same level of oversight for all ketamine therapy indications"? Or even more restrictively, "France authorized it for suicidal crisis, so that's the only indication we should formally recognize"?
As organizations such as the American Society of Ketamine for Physicians, Psychotherapists & Practitioners (ASKP3) work to develop standardized protocols for treatment-resistant depression and chronic pain, France's move signals that the regulatory landscape is shifting faster than many anticipated. The validation is exciting. The potential for regulations designed by those outside the ketamine therapy community (who may not understand the full scope of what's being treated) is the concern.
💡 KEY TAKEAWAYS
- First national validation of IV racemic ketamine: France formally authorized the formulation many in the ketamine therapy community already use and prefer, lending international credibility to a treatment providers have been offering off-label for years.
- Narrow framework, broad implications: France's authorization is limited to severe suicidal crisis in hospital-based settings with high-surveillance protocols, much more restrictive than how U.S. providers currently use ketamine for treatment-resistant depression, PTSD, chronic pain, and other conditions.
- Potential regulatory precedent concerns: France's strict, crisis-only framework could become the model that U.S. regulators point to when formalizing ketamine therapy standards, potentially limiting scope of practice or requiring hospital-level oversight for all applications.
- Regulatory landscape shifting faster than field standardization: While ASKP3 works to develop protocols for treatment-resistant depression and chronic pain, France's move signals that formal regulatory frameworks may arrive before the ketamine therapy community has defined its own standards.
What This Means for Providers:
France validated IV racemic ketamine as a legitimate psychiatric intervention, which is encouraging. But the framework they authorized is narrower than current U.S. practice: hospital-based, suicidal-crisis-only, with high-surveillance protocols. If this becomes the regulatory template that U.S. regulators adopt, office-based providers treating depression, PTSD, and chronic pain could face pressure to conform to more restrictive standards or defend their broader scope of practice.
Texas Medical Board Update: PKT Rules Still Pending
Just a quick regulatory update: if you recall on January 2, 2026 the Texas Medical Board's proposed regulations for ketamine therapy clinics, that story is still very much alive.
As of early May 2026, those rules are not yet law. The Board published the proposed Parenteral Ketamine Therapy (PKT) regulations in January, opened a public comment period through February, and is now circulating a revised draft that they're expected to vote on in June 2026.
What Hasn't Changed
The Board's direction remains clear: they're pushing for mandatory clinic registration, tighter physician oversight, strict monitoring standards, and a ban on in-home parenteral ketamine.
So while Texas hasn't crossed the line into final rulemaking yet, the handwriting is on the wall: ketamine therapy is no longer a "wild West" corner of the mental health space.
Why This Matters
For clinics in Texas and beyond, this is less about a surprise crackdown and more about watching how one state is trying to define the floor for how ketamine should be regulated across the country.
View sources and references | Read our full Texas regulations analysis
💡 KEY TAKEAWAYS
- Rules still pending but direction is set: Texas Medical Board published proposed PKT regulations in January 2026, completed public comment in February, and expects to vote on revised rules in June 2026. Final adoption is imminent.
- Four core requirements remain: Mandatory clinic registration, onsite physician presence during treatment, enhanced monitoring standards, and complete ban on in-home parenteral ketamine are all still in the revised draft.
- Texas is setting the floor, not the ceiling: These aren't aspirational best practices. They're minimum operating standards that define what ketamine therapy should look like when formally regulated.
- National implications beyond state borders: Other state medical boards are watching Texas closely. What passes here could become the template for ketamine regulation nationwide.
What This Means for Providers:
Texas is defining baseline regulatory standards for ketamine therapy, and other states are watching. Providers in states without formal ketamine regulations should treat Texas's framework as a preview of future requirements, not an isolated experiment. The shift from unregulated to structured ketamine practice is happening now. Providers without documentation systems, monitoring protocols, and physician oversight infrastructure are running out of runway.
President Trump's April 18, 2026 executive order "Accelerating Medical Treatments for Serious Mental Illness" directs FDA and DEA to fast-track psychedelic therapy research and access, elevating psilocybin, MDMA-type compounds, and ibogaine to federal priority status with $50 million in research funding.
Trump Executive Order: Federal Fast-Track for Psychedelic Therapy
At the federal level, President Trump has just reshaped the psychedelic therapy landscape with a major executive order. On April 18, 2026, he signed "Accelerating Medical Treatments for Serious Mental Illness," which directs multiple agencies (especially the FDA and DEA) to speed up research and access to psychedelic drugs for serious mental health conditions.
What the Order Actually Does
The order instructs the FDA to expedite the review of psychedelics that meet certain criteria, including compounds with Breakthrough Therapy status, and to prioritize developments like psilocybin-based treatments for depression and PTSD-related MDMA-type products.
It opens a Right-to-Try-style pathway for eligible patients to access investigational psychedelic drugs under FDA oversight, specifically calling out ibogaine compounds for people with serious mental health or substance use disorders.
The administration also directs $50 million through HHS and the ARPA-H program to match state-government investments into psychedelic research, with Texas's ibogaine research push named as an early target.
How It Hits the Industry
For clinicians and ketamine-focused operators, the key point is that the order is not limited to ketamine. It's a broader "psychedelic-assisted therapy" policy shift that elevates psilocybin, MDMA-like compounds, and ibogaine to the federal priority list.
Analysts emphasize that it signals the White House wants Schedule I-style restrictions rolled back as soon as these drugs clear Phase 3 trials and gain FDA approval, which could accelerate recategorization and reimbursement conversations.
💡 KEY TAKEAWAYS
- Federal prioritization of psychedelic therapy: The executive order directs FDA and DEA to fast-track review and access for psychedelics including psilocybin, MDMA-type compounds, and ibogaine. Treating these compounds as legitimate medical interventions for serious mental health conditions.
- Right-to-Try pathway for investigational compounds: Eligible patients can now access investigational psychedelic drugs under FDA oversight before full approval, with ibogaine specifically called out for mental health and substance use disorders.
- $50 million in federal matching funds: HHS and ARPA-H will match state-level psychedelic research investments, with Texas's ibogaine program named as an early funding target, signaling coordinated federal-state research push.
- Schedule I reclassification on the horizon: The administration wants Schedule I restrictions removed as compounds clear Phase 3 trials and gain FDA approval, which could accelerate both regulatory reclassification and insurance reimbursement conversations.
What This Means for Providers:
The federal government states now that they are treating psychedelic-assisted therapy as legitimate medicine, which means likely federal-level regulatory expectations. Regulation, monitoring, and outcome tracking could shift from clinic-level best practices to standards set by FDA and DEA. Providers without rigorous documentation systems, standardized protocols, and outcome-tracking infrastructure could face scrutiny from multiple regulatory directions simultaneously.
The REMS Advantage: What Regulatory-Ready Looks Like
Before wrapping up, here's one observation that connects everything we've covered.
As the FDA, DEA, and state boards continue moving in this direction, one pattern is becoming hard to ignore: the closer your clinic already looks like a REMS-style facility, the better positioned you are for whatever comes next.
What Is REMS?
REMS stands for Risk Evaluation and Mitigation Strategy. These are FDA-designed programs that ensure high-risk, high-impact drugs are only administered in tightly controlled settings, with strict eligibility checks, trained staff, continuous monitoring, and documented follow-up.
This isn't a hypothetical framework. It already exists in our space.
REMS in Practice Today
Esketamine (Spravato) can only be administered through FDA-certified, REMS-compliant sites right now. That means clinics that have gone through that certification process already have the infrastructure, the protocols, and the electronic documentation systems that regulators are likely to expect from future psychedelic therapies.
When policymakers and researchers talk about building REMS-style frameworks for psilocybin, MDMA-type compounds, or new ketamine-based products, they're not describing something that has to be invented from scratch. They're pointing to a model that already exists in clinics treating Spravato patients today.
The Strategic Takeaway
Regulatory advantage is shifting toward structure, not flexibility. The clinics most likely to have a seat at the table in the next wave of FDA-approved psychedelic therapies won't necessarily be the biggest or the most established.
They'll be the ones that already look like regulated, accountable, REMS-adjacent environments: where every patient is tracked, every dose is documented, and every risk is being actively managed.
That's not just good compliance. That's good positioning.
💡 KEY TAKEAWAYS
- REMS is the existing model for psychedelic regulation: Risk Evaluation and Mitigation Strategies already govern esketamine (Spravato) administration through FDA-certified sites with strict eligibility, monitoring, and documentation requirements. This framework will likely expand to future psychedelic therapies.
- Infrastructure matters more than size: Clinics that have already achieved REMS certification have the electronic documentation systems, trained staff protocols, and continuous monitoring infrastructure that regulators will likely expect from psilocybin, MDMA-type compounds, and new ketamine products.
- Regulatory advantage favors structure over flexibility: Future FDA-approved psychedelic therapies will likely prioritize clinics that already operate as regulated, accountable environments with comprehensive patient tracking and risk management, not necessarily the largest or most established practices.
- REMS-adjacent positioning is strategic, not just compliant: Building REMS-style infrastructure now could support positioning for first access to next-generation FDA-approved psychedelic treatments in the future.
What This Means for Providers:
The next wave of FDA-approved psychedelic therapies will be distributed through REMS-style frameworks similar to what already exists for Spravato. Clinics robust electronic documentation systems, standardized monitoring protocols, and certified staff infrastructure will more likely meet the baseline eligibility requirements to administer controlled psychedelic compounds. The question isn't whether to build REMS-adjacent infrastructure. It's whether to build it now and potentially gain early access, or build it later and watch competitors serve patients first.
Ketamine therapy providers reviewing clinical protocols and documentation systems in response to converging regulatory pressures from legal prosecution (Perry case), international frameworks (France), state regulations (Texas), and federal policy (Trump EO)—accountability and structured oversight are no longer optional.
The Pattern Emerging: Accountability Isn't Optional Anymore
Let's zoom out for a second, because these stories aren't unrelated.
A 15-year prison sentence for a black-market ketamine supplier, and 30 months for a physician who lost the thread of what supervised care actually means. A country on the other side of the world building the most rigorous ketamine framework we've ever seen at a national level. A state medical board drawing a hard line on minimum operating standards. A federal executive order that puts psychedelic-assisted therapy on the official policy agenda.
What connects all of it is accountability.
This field is being watched, shaped, and in some cases prosecuted. The courts are holding physicians responsible for ketamine that moves outside clinical supervision. International regulators are building frameworks with mandatory monitoring. State boards are defining operational floors, not ceilings. The federal government is beginning to treat psychedelics as legitimate medicine. which means further legitimate regulatory expectations.
And the clinics that already have REMS-style infrastructure? They're not scrambling to catch up. They're more positioned for what's likely next.
The providers who are going to come out of this moment well are the ones who aren't waiting to be told what good looks like. They're building systems now. They're implementing monitoring protocols now. They're treating ketamine therapy like the serious psychiatric intervention it is. Doing this not because regulators are forcing them to, but because that's what they believe is medically and ethically correct.
The question isn't whether this shift is coming. It's whether you're preparing for it now, or waiting until it arrives.
Professional Education Disclaimer: This content is intended exclusively for licensed healthcare professionals and should not be used by patients for self-treatment or self-education. The information presented reflects individual provider experiences and should not replace clinical judgment, professional training, or comprehensive research. Healthcare providers must conduct their own due diligence, consult current literature, and evaluate treatment approaches within their specific practice context and regulatory environment. This educational content does not constitute medical advice for specific patients or clinical situations - treatment decisions should always be based on individual patient assessment and adherence to professional medical standards.
Frequently Asked Questions
What was the final sentence in the Matthew Perry ketamine case?
In April 2026, Jasveen Sangha (the "Ketamine Queen") received 15 years in federal prison. This is the harshest sentence in the case. Two physicians were also sentenced: Dr. Salvador Plasencia received 30 months in federal prison for distributing ketamine to Perry, and Dr. Mark Chavez received eight months of home confinement, three years supervised release, and 300 hours of community service for conspiring to distribute ketamine. The case prosecuted five people total, establishing that legal accountability extends to physicians who enable ketamine access outside proper clinical supervision.
What did France approve for ketamine therapy in 2026 and why does it matter for U.S. providers?
In March 2026, France became the first country to formally authorize IV racemic ketamine (not esketamine) specifically for adults in severe suicidal crisis. The authorization requires a structured framework: careful patient selection, continuous monitoring during and after infusion, and repeated suicidal ideation assessments in hospital-based settings. While this validates the formulation many U.S. providers have been using off-label for years, France's framework is much narrower than current U.S. practice. U.S. providers treat a broader scope (treatment-resistant depression, PTSD, chronic pain) often in office-based settings. The concern is whether France's strict, crisis-only, hospital-based framework could become the regulatory template that U.S. regulators point to, potentially limiting scope of practice or requiring hospital-level oversight for all ketamine therapy applications.
Are the Texas ketamine clinic regulations finalized yet?
As of early May 2026, no. The Texas Medical Board's Parenteral Ketamine Therapy (PKT) regulations are not yet law. The Board published proposed rules in January 2026, completed public comment in February, and is expected to vote on the revised draft in June 2026. The proposed requirements include mandatory clinic registration, onsite physician presence during treatment, enhanced monitoring standards, and a ban on in-home parenteral ketamine.
What does Trump's psychedelic executive order mean for ketamine providers?
A: President Trump's April 18, 2026 executive order "Accelerating Medical Treatments for Serious Mental Illness" fast-tracks psychedelic therapy research and access but focuses primarily on psilocybin, MDMA-type compounds, and ibogaine, not ketamine specifically. For ketamine providers, the key takeaway is that psychedelic-assisted therapy is now a federal priority, which means regulation, monitoring, and outcome-tracking expectations are shifting from clinic-level best practices to federal-level standards. Providers should expect increased scrutiny around documentation, safety protocols, and clinical outcomes.
Do I need REMS certification to operate a ketamine clinic?
Currently, REMS (Risk Evaluation and Mitigation Strategy) certification is only required for esketamine (Spravato) administration, not for off-label racemic ketamine infusions. However, REMS-style infrastructure (strict eligibility checks, continuous monitoring, documented follow-up, electronic tracking systems) is increasingly becoming the regulatory standard. Clinics with REMS-adjacent systems are better positioned for future FDA-approved psychedelic therapies, which will likely require similar frameworks.
How will these regulatory changes affect ketamine therapy providers in 2026?
Four trends are converging: criminal prosecution of physicians who enable unmonitored ketamine use (Perry case), international adoption of high-surveillance frameworks (France), state-level minimum operating standards (Texas), and federal prioritization of psychedelic therapy (Trump EO). Together, these signal that accountability, documentation, and structured monitoring are no longer optional. Providers without robust safety protocols, outcome tracking, and physician oversight will face increasing regulatory pressure from multiple directions—state medical boards, federal agencies, and legal liability.
What is the Matthew Perry ketamine case and why does it matter for providers?
Matthew Perry died in October 2023 from acute ketamine effects after receiving treatment under medical supervision for depression, then sourcing higher doses through illicit channels. Five people were criminally charged including two physicians who received federal prison sentences for distributing ketamine outside proper oversight. The case matters because it establishes legal precedent: courts will hold physicians accountable when ketamine transitions from supervised clinical use to unmonitored, at-home administration, even if treatment began legitimately.
Sources and References
Matthew Perry Case
U.S. Department of Justice Press Release - Official sentencing announcement
New York Times - Case analysis and legal implications
Associated Press - Sentencing details
NBC News - Court proceedings coverage
CNN - Accountability analysis
BBC - International coverage
France Ketamine Authorization
The Lancet - Clinical trial data and authorization details
National Elf Service - Evidence review
PubMed - Research summary
Clinical Trial Vanguard - Regulatory analysis
LinkedIn - Tadeusz Hawrot - Industry perspective
Texas Medical Board PKT Regulations
KSAT News - Proposed rule coverage
Texas Medical Board - Official rule changes page
Texas Health Law - Legal analysis
Ketamine StartUp Analysis - Detailed breakdown of proposed requirements
Trump Executive Order
White House Official Order - Full executive order text
White House Fact Sheet - Policy summary
FDA Press Release - Agency response
Washington Post Opinion - Critical analysis
Washington Post Opinion - Supportive analysis
Harvard Law Petrie-Flom Center - Legal expert Q&A
STAT News - Healthcare industry perspective
TIME - Policy explainer
Foley & Lardner LLP - Legal firm analysis
NPR - Public radio coverage
REMS Framework
Spravato REMS Official - Official REMS program site
Spravato HCP Center Locator - Certified treatment centers
Texas Medicaid TMHP - Coverage information
Seattle Regen REMS Certification - Clinic certification case study
Lumin Health REMS Standards - Safety standards overview
AgencyIQ FDA Analysis - Regulatory insights
SSRN Legal Paper - Academic legal analysis
Matthew Perry sentencing, France's IV ketamine authorization, Texas PKT rules, and Trump's psychedelic EO signal major regulatory shifts for ketamine providers.
Matthew Perry sentencing, France's IV ketamine authorization, Texas PKT rules, and Trump's psychedelic EO signal major regulatory shifts for ketamine providers.